Canada's generic drug sector could face more change from Ontario court ruling and possible Canada-EU trade deal

摘要

The past year has produced significant change for Canada's generic drug industry, as provincial governments have capped pricing and in some cases, restricted commercial terms between generic companies and pharmacies. And more change may be on the horizon. A recent Ontario court ruling and European trade demands aimed at delaying introduction of generic versions of brand-name drugs could also have an impact on Canadian generic drug manufacturers.